IP Library Granted Patent US 7,169,761
Granted Patent B2
US 7,169,761 · App. 10/491,618 · Granted Jan 30, 2007

Azulene derivatives and salts thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,761
App. No.
10/491,618
Granted
Jan 30, 2007
Kind
B2
Abstract

The present invention provides an azulene derivative and a salt thereof, wherein an azulene ring is bonded to a benzene ring directly or via a lower alkylene which may be substituted with a halogen atom and the benzene ring is directly bonded to the glucose residue, and it is usable as a Na + -glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes-related diseases such as insulin-resistant diseases and obesity.

Claims (30)

1. An azulene derivative of following formula (I) or a salt thereof:

wherein R 1 to R 4 individually represent a hydrogen atom, optionally substituted lower alkyl, —C(═O)-optionally substituted lower alkyl, or —optionally substituted lower alkylene-optionally substituted aryl,

R 5 to R 12 individually represent a hydrogen atom, an optionally substituted lower alkyl, halogen atom, —OH, —O-optionally substituted lower alkyl, -optionally substituted lower alkylene-OH, -optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-optionally substituted aryl, -optionally substituted lower alkylene-O—C(═O)-optionally substituted lower alkyl, —COOH, nitro, cyano, amino, substituted amino, or —C(═O)—O-optionally substituted lower alkyl, and

A represents a bond or an optionally substituted lower alkylene,

wherein -A- may be bonded to any one of the positions 1–8 of the azulene ring, and any two of R 5 , R 6 , and R 7 may form a benzene ring together with the adjacent carbon atoms, and

wherein optionally substituted chemical groups are substituted with a haloaen atom, —OH, -lower alkylene-OH, —COOH, —C(═O)—O-lower alkyl, nitro, cyano, or an amino group.

2. The azulene derivative or the salt thereof according to claim 1 , wherein the optionally substituted lower alkyl, —C(═O)-optionally substituted lower alkyl, and —optionally substituted lower alkylene-optionally substituted aryl represented by R 1 to R 4 in the above formula (I) are respectively a lower alkyl, —C(═O)-lower alkyl, and -lower alkylene-aryl, the optionally substituted lower alkyl, —O-optionally substituted lower alkyl, -optionally substituted lower alkylene-OH, -optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-optionally substituted alkyl, —O-optionally substituted lower alkylene-optionally substituted aryl, -optionally substituted lower alkylene-O—C(═O)-optionally substituted lower alkyl, and —C(═O)—O-optionally substituted lower alkyl represented by R 5 to R 12 in the formula (I) are respectively a lower alkyl or a halogen-substituted lower alkyl, —O-lower alkyl, -lower alkylene-OH, -lower alkylene-O-lower alkyl, —O-lower alkylene-O-lower alkyl, —O-lower alkylene-aryl, -lower alkylene-O—C(═O)-lower alkyl, and —C(═O)—O-lower alkyl,

wherein the optionally substituted lower alkylene represented by A in the above formula (I) is a lower alkylene or a halogen-substituted lower alkylene, and

wherein optionally substituted chemical groups are substituted with a halogen atom, —OH, -lower alkylene-OH, —COOH, —C(═O)—O-lower alkyl, nitro, cyano, or an amino group.

3. The azulene derivative or the salt thereof according to claim 1 , wherein the group represented by A in the above formula (I) is a lower alkylene.

4. The azulene derivative or the salt thereof according to claim 3 , wherein the group represented by A in the above formula (I) is a methylene.

5. The azulene derivative or the salt thereof according to claim 1 , wherein the groups represented by R 1 to R 4 in the above formula (I) are hydrogen atoms.

6. The azulene derivative or the salt thereof according to claim 1 , wherein the azulene derivative of the above formula (I) is at least one compound selected from the group consisting of 1,5-anhydro-1-[3-(azulen-2-ylmethyl)phenyl]hexytol, 1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-methoxyphenyl]hexytol, 1,5-anhydro-1-[3-(azulen-2-ylmethyl)-5-methoxyphenyl]hexytol, 1,5-anhydro-1-[3-(azulen-2-ylmethyl)-4-methoxyphenyl]hexytol, 1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-ethoxyphenyl]hexytol, 1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-methylphenyl]hexytol, 1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]hexytol, 1,5-anhydro-[5-(azulen-2-ylmethyl)-2-fluorophenyl]hexytol, 1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2,4-dimethoxyphenyl]hexytol, and 1,5-anhydro-1-[4-(azulen-2-ylmethyl)-1-methoxy-2-naphthyl]hexytol.

7. A pharmaceutical composition containing an effective amount of an azulene derivative of following formula (I) or a salt thereof:

wherein R 1 to R 4 individually represent a hydrogen atom, optionally substituted lower alkyl, —C(═O)-optionally substituted lower alkyl, or -optionally substituted lower alkylene-optionally substituted aryl,

R 5 to R 12 individually represent a hydrogen atom, an optionally substituted lower alkyl, halogen atom, —OH, —O-optionally substituted lower alkyl, -optionally substituted lower alkylene-OH, -optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-optionally substituted aryl, -optionally substituted lower alkylene-O—C(═O)-optionally substituted lower alkyl, —COOH, nitro, cyano, amino, substituted amino, or —C(═O)—O-optionally substituted lower alkyl, and

A represents a bond or an optionally substituted lower alkylene,

wherein -A- may be bonded to any one of the positions 1–8 of the azulene ring, and any two of R 5 , R 6 , and R 7 may form a benzene ring together with the adjacent carbon atoms, and

wherein optionally substituted chemical groups are substituted with a halogen atom, —OH, -lower alkylene-OH, —COOH, —C(═O)—O-lower alkyl, nitro, cyano, or an amino group

and pharamaceutically acceptabe adjuvants.

8. A method of inhibiting a Na + -glucose cotransporter comprising administering an effective amount of the pharmaceutical composition according to claim 7 to a patient in need thereof.

9. A method for treating diabetes comprising administering an effective amount of an azulene derivative of following formula (I) or a salt thereof to a patient in need thereof:

wherein R 1 to R 4 individually represent a hydrogen atom, optionally substituted lower alkyl, —C(═O)-optionally substituted lower alkyl, or —optionally substituted lower alkylene-optionally substituted aryl,

R 5 to R 12 individually represent a hydrogen atom, an optionally substituted lower alkyl, halogen atom, —OH, —O-optionally substituted lower alkyl, -optionally substituted lower alkylene-OH, -optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-optionally substituted aryl, -optionally substituted lower alkylene-O—C(═O)-optionally substituted lower alkyl, —COOH, nitro, cyano, amino, substituted amino, or —C(═O)—O-optionally substituted lower alkyl, and

A represents a bond or an optionally substituted lower alkylene,

wherein -A- may be bonded to any one of the positions 1–8 of the azulene ring, and any two of R 5 , R 6 , and R 7 may form a benzene ring together with the adjacent carbon atoms, and

wherein optionally substituted chemical groups are substituted with a halogen atom, —OH, -lower alkylene-OH, —COOH, —C(═O)—O-lower alkyl, nitro, cyano, or an amino group.

10. A method for treating diabetes comprising administering an effective amount of the azulene derivative or the salt thereof according to claim 9 to a patient in need thereof, wherein the optionally substituted lower alkyl, —C(═O)-optionally substituted lower alkyl, and -optionally substituted lower alkylene-optionally substituted aryl represented by R 1 to R 4 in the above formula (I) are respectively a lower alkyl, —C(═O)-lower alkyl, and -lower alkylene-aryl, the optionally substituted lower alkyl, —O-optionally substituted lower alkyl, -optionally substituted lower alkylene-OH, -optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-O-optionally substituted lower alkyl, —O-optionally substituted lower alkylene-optionally substituted aryl, -optionally substituted lower alkylene-O—C(═O)-optionally substituted lower alkyl, and —C(═O)—O-optionally substituted lower alkyl represented by R 5 to R 12 in the formula (I) are respectively a lower alkyl or a halogen-substituted lower alkyl, —O-lower alkyl, -lower alkylene-OH, -lower alkylene-O-lower alkyl, —O-lower alkylene-O-lower alkyl, —O-lower alkylene-aryl, -lower alkylene-O—C(═O)-lower alkyl, and —C(═O)—O-lower alkyl,

wherein the optionally substituted lower alkylene represented by A in the above formula (I) is a lower alkylene or a halogen-substituted lower alkylene, and

wherein optionally substituted chemical groups are substituted with a halogen atom, —OH, -lower alkylene-OH, —COOH, —C(═O)—O-lower alkyl, nitro, cyano, or an amino group.

Assignments (2)
CHANGE OF NAME Recorded Nov 16, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016784/0361 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2004
From: TOMIYAMA, HIROSHI; NODA, ATSUSHI; KITTA, KAYOKO; KOBAYASHI, YOSHINORI; IMAMURA, MASAKAZU; MURAKAMI, TAKESHI; IKEGAI, KAZUHIRO; SUZUKI, TAKAYUKI; KUROSAKI, EIJI
To: YAMANOUCHI PHARMACEUTICAL CO., LTD.; KOTOBUKI PHARMACEUTICAL CO., LTD.
Reel/Frame 016066/0128 →